<DOC>
	<DOCNO>NCT00657423</DOCNO>
	<brief_summary>To study impact endostar combine docetaxel cisplatin angiogenesis non-small cell lung cancer , patient randomly assign group one ( endostar combine docetaxel cisplatin ) group two ( docetaxel cisplatin ) . - The serum concentration Endostatin , VEGF bFGF determine . - Blood circulate endothelial cell ( CECs ) circulate hematopoietic progenitor cell ( CPCs ) measure flow cytometer . - Statistical analysis apply study relationship level Endostatin , VEGF , bFGF , CECs CPCs clinical outcome objective response rate ( ORT ) , time progression ( TTP ) , mean survival time ( MST ) , toxicity quality life ( QOL ) .</brief_summary>
	<brief_title>Impact Endostar Combined With Chemotherapy Angiogenesis Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>To study impact endostar combine docetaxel cisplatin angiogenesis non-small cell lung cancer , patient randomly assign experimental group ( endostar combine docetaxel cisplatin ) control group ( docetaxel cisplatin ) . - serum concentration Endostatin , VEGF bFGF determine . - Blood circulate endothelial cell ( CECs ) circulate hematopoietic progenitor cell ( CPCs ) measure flow cytometer . - clinical parameter objective response rate ( ORT ) , time progression ( TTP ) mean survival time ( MST ) collect accord WHO criterion . - toxicity record accord NCI-CTC v3.0 . - Quality life self-assessed use European Organisation Research Treatment Cancer ( EORTC ) QLQ C-30 questionnaire . - Statistical analysis apply study relationship level Endostatin , VEGF , bFGF , CECs CPCs clinical outcome ORT , TTP , MST , toxicity QOL .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Clinical diagnosis advance metastatic NSCLC ( confirm histologically , tumor measurable clinical and/or radiologic examination . Have Eastern Cooperative Oncology Group performance status 0 2 . Adequate renal , cardiac , hepatic , hematologic function indicate follow parameter : absolute neutrophil count 2 x ninth power ten/L , thrombocytes 100 x ninth power ten/L , hemoglobin 10 g/dL , total bilirubin 1.25x upper limit normal range ( ULN ) , ALT AST 1.5x ULN , alkaline phosphatase 5x ULN , creatinine 1.15x ULN . Known brain metastasis secondary neoplasia . Myocardial insufficiency myocardial infarction within precede 6 month . Severe renal hepatic insufficiency . Preexisting motor sensor neurotoxicity WHO grade 2 . Severe psychologic disease . Active infection , condition could compromise protocol compliance . Simultaneous administration antineoplastic medication . Clinically significant hemoptysis . Pregnancy and/or lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Endostatins</keyword>
	<keyword>Vascular Endothelial Growth Factors</keyword>
	<keyword>Fibroblast Growth Factors</keyword>
	<keyword>Survival Rate</keyword>
</DOC>